These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15059912)

  • 1. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen.
    Kasuya H; Pawlik TM; Mullen JT; Donahue JM; Nakamura H; Chandrasekhar S; Kawasaki H; Choi E; Tanabe KK
    Cancer Res; 2004 Apr; 64(7):2561-7. PubMed ID: 15059912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of herpes simplex virus 1 replication using tumor-associated promoters.
    Mullen JT; Kasuya H; Yoon SS; Carroll NM; Pawlik TM; Chandrasekhar S; Nakamura H; Donahue JM; Tanabe KK
    Ann Surg; 2002 Oct; 236(4):502-12; discussion 512-3. PubMed ID: 12368679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.
    Kurihara T; Brough DE; Kovesdi I; Kufe DW
    J Clin Invest; 2000 Sep; 106(6):763-71. PubMed ID: 10995787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.
    Doloff JC; Jounaidi Y; Waxman DJ
    Cancer Gene Ther; 2011 Mar; 18(3):153-66. PubMed ID: 20865021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.
    Nakamura H; Kasuya H; Mullen JT; Yoon SS; Pawlik TM; Chandrasekhar S; Donahue JM; Chiocca EA; Chung RY; Tanabe KK
    J Clin Invest; 2002 Apr; 109(7):871-82. PubMed ID: 11927614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter.
    Chen L; Chen D; Manome Y; Dong Y; Fine HA; Kufe DW
    J Clin Invest; 1995 Dec; 96(6):2775-82. PubMed ID: 8675647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
    Yamamoto S; Deckter LA; Kasai K; Chiocca EA; Saeki Y
    Gene Ther; 2006 Dec; 13(24):1731-6. PubMed ID: 16871231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model.
    Nawa A; Nozawa N; Goshima F; Nagasaka T; Kikkawa F; Niwa Y; Nakanishi T; Kuzuya K; Nishiyama Y
    Gynecol Oncol; 2003 Oct; 91(1):81-8. PubMed ID: 14529666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
    Lee CY; Rennie PS; Jia WW
    Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
    Fu X; Zhang X
    Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model.
    Gupta VK; Park JO; Kurihara T; Koons A; Mauceri HJ; Jaskowiak NT; Kufe DW; Weichselbaum RR; Posner MC
    Gene Ther; 2003 Feb; 10(3):206-12. PubMed ID: 12571627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoter-driven expression of the human sodium-iodide symporter.
    Chen RF; Li ZH; Pan QH; Zhou JJ; Tang QB; Yu FY; Zhou QB; Wang J; Chen JS
    Pancreatology; 2007; 7(5-6):505-13. PubMed ID: 17912014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Editing of Herpes Simplex Virus 1 Enables Interferon Induction and Viral Replication That Destroy Malignant Cells.
    Liu X; He B
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
    Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
    Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect.
    Fu X; Tao L; Jin A; Vile R; Brenner MK; Zhang X
    Mol Ther; 2003 Jun; 7(6):748-54. PubMed ID: 12788648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
    Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy.
    Deharvengt S; Wack S; Aprahamian M; Hajri A
    J Gene Med; 2005 May; 7(5):672-80. PubMed ID: 15580629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
    Todo T; Martuza RL; Rabkin SD; Johnson PA
    Proc Natl Acad Sci U S A; 2001 May; 98(11):6396-401. PubMed ID: 11353831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.
    Nakamura H; Mullen JT; Chandrasekhar S; Pawlik TM; Yoon SS; Tanabe KK
    Cancer Res; 2001 Jul; 61(14):5447-52. PubMed ID: 11454690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.